Loading
A phase 1/2 trial of GT719 Injection in non-Hodgkin lymphoma, run by Grit Biotechnology, now recruiting.
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies is a phase 1/2 interventional study registered as NCT06948981 by Grit Biotechnology, with 46 participants planned, started 2025-04-18 and due to reach its primary completion in 2028-04-17. Interventions recorded: GT719 Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Grit Bio and the tag pipeline.
Shares Grit Bio and the tag pipeline.
Shares CD19, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/